TY - JOUR
T1 - Pathophysiology and treatment of enteric hyperoxaluria
AU - Witting, Celeste
AU - Langman, Craig B.
AU - Assimos, Dean
AU - Baum, Michelle A.
AU - Kausz, Annamaria
AU - Milliner, Dawn
AU - Tasian, Greg
AU - Worcester, Elaine
AU - Allain, Meaghan
AU - West, Melissa
AU - Knauf, Felix
AU - Lieske, John C.
N1 - Funding Information:
M. Allain reports employment at the American Society of Nephrology. D. Assimos has been on editorial boards for Journal of Endourology, Journal of Urology,and Urolithiasis.M.A. Baumis onthe scientific advisory boards for Dicerna, Dent Disease Foundation, Oxalosis/Hyperoxaluria Foundation, and Retrophin, and is a consultant for Retrophin. A. Kausz is employed by and has ownership interest in Allena Pharmaceuticals, Inc, which is developing a product for the treatment of enteric hyperoxalura. She is also on the KHI Board of Directors. F. Knauf is a consultant for Allena Pharmaceuticals, Alnylam Pharmaceuticals, and OxThera Pharmaceuticals, and receives funding from Dicerna Pharmaceuticals and Fresenius Medical Care. C.B. Langman is a consultant for Alexion Pharmaceuticals, Allena Pharmaceuticals, and Dicerna Pharmaceuticals, and receives researching funding from Lurie Children’s Hospital, Achillion and Alexicon Pharmaceuticals; Lurie Children’s Hospital of Chicago, Alexion; and Lurie Children’s Hospital, Ul-tragenyx. J.C. Lieske reports receiving grants and other from Allena, and reports serving on the advisory boards of Novobiom and Synlogic, during the conduct of the study. He is a consultant for Allena, Alnylam, American Board of Internal Medicine, Dicerna, Orfan, OxThera, Retrophin, and Siemens; receives funding from Allena, Alnylam, Dicerna, OxThera, Retrophin, and Siemens; and serves on the advisory board for Orfan. D. Milliner reports serving as consultant (contracts paid directly to Mayo Clinic) for Allena Pharmaceuticals, consultant (contracts paid directly to Mayo Clinic) and on the advisory committee for Alnylam Pharmaceuticals, consultant and chair of Data Safety and Monitoring Committtee (contractspaiddirectlytoMayoClinic)forDicernaPharmaceuticals, consultant and chair of the Data Safety and Monitoring Board (contracts paid directly to Mayo Clinic) for OxThera Pharmaceuticals, member of Synologic Medical Advisory Panel (contracts paid directly to Mayo Clinic) for Synlogic, and on the editorial board for Urolithiasis. D. Milliner also reports receiving National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant U54-DK083908, outside the submitted work. G. Tasian is a consultant for Allena Pharmaceuticals; reports receiving grants from the Patient-Centered Outcomes Research Institute and NIDDK; and reports
Funding Information:
We would like to acknowledge Kim Hollander and Julie Bertarelli from the OHF (www.ohf.org) for their initiation of this project and continued support, along with the patients with enteric hyper-oxaluria and their families who motivated this work. This work was supported by the KHI, a public-private partnership between the American Society of Nephrology, the US Food and Drug Administration, and >100 member organizations and companies to enhance patient safety and foster innovation in kidney disease. KHI funds were used to defray costs incurred during the conduct of the project, including project management support, which was expertly provided by American Society of Nephrology staff members Meaghan Allain and Melissa West. There was no honorarium or other financial support provided to KHI workgroup members. The authors of this paper had final review authority and are fully responsible for its content. KHI makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the members of the workgroup. More information on KHI, the workgroup, or the conflict of interest policy can be found at www.kidneyhealthinitiative.org.
Publisher Copyright:
© 2021 by the American Society of Nephrology.
PY - 2021
Y1 - 2021
N2 - Enteric hyperoxaluria is a distinct entity that can occur as a result of a diverse set of gastrointestinal disorders that promote fat malabsorption. This, in turn, leads to excess absorption of dietary oxalate and increased urinary oxalate excretion. Hyperoxaluria increases the risk of kidney stones and, in more severe cases, CKD and even kidney failure. The prevalence of enteric hyperoxaluria has increased over recent decades, largely because of the increased use of malabsorptive bariatric surgical procedures for medically complicated obesity. This systematic review of enteric hyperoxaluria was completed as part of a Kidney Health Initiative–sponsored project to describe enteric hyperoxaluria pathophysiology, causes, outcomes, and therapies. Current therapeutic options are limited to correcting the underlying gastrointestinal disorder, intensive dietary modifications, and use of calcium salts to bind oxalate in the gut. Evidence for the effect of these treatments on clinically significant outcomes, including kidney stone events or CKD, is currently lacking. Thus, further research is needed to better define the precise factors that influence risk of adverse outcomes, the long-term efficacy of available treatment strategies, and to develop new therapeutic approaches.
AB - Enteric hyperoxaluria is a distinct entity that can occur as a result of a diverse set of gastrointestinal disorders that promote fat malabsorption. This, in turn, leads to excess absorption of dietary oxalate and increased urinary oxalate excretion. Hyperoxaluria increases the risk of kidney stones and, in more severe cases, CKD and even kidney failure. The prevalence of enteric hyperoxaluria has increased over recent decades, largely because of the increased use of malabsorptive bariatric surgical procedures for medically complicated obesity. This systematic review of enteric hyperoxaluria was completed as part of a Kidney Health Initiative–sponsored project to describe enteric hyperoxaluria pathophysiology, causes, outcomes, and therapies. Current therapeutic options are limited to correcting the underlying gastrointestinal disorder, intensive dietary modifications, and use of calcium salts to bind oxalate in the gut. Evidence for the effect of these treatments on clinically significant outcomes, including kidney stone events or CKD, is currently lacking. Thus, further research is needed to better define the precise factors that influence risk of adverse outcomes, the long-term efficacy of available treatment strategies, and to develop new therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=85097743445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097743445&partnerID=8YFLogxK
U2 - 10.2215/CJN.08000520
DO - 10.2215/CJN.08000520
M3 - Article
C2 - 32900691
AN - SCOPUS:85097743445
SN - 1555-9041
VL - 16
SP - 487
EP - 495
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 3
ER -